GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
This is a proof of concept (POC) single arm study of GW640385, a protease inhibitor, in
combination with RTV and 2 or more nucleoside reverse transcriptase inhibitors (NRTI)
backbone. This study has a 48 week duration and is open to both treatment naive and
experienced patients who are HIV positive. There are 3 intensive pharmacokinetic (PK) visits.